AAPL314.37+1.71 (+0.55%) ▲|ABBV258.40+3.64 (+1.43%) ▲|ABT96.54+0.91 (+0.95%) ▲|ACN143.40+6.44 (+4.70%) ▲|ADBE230.12+12.05 (+5.52%) ▲|AMAT542.03-50.76 (-8.56%) ▼|AMD514.69-37.36 (-6.77%) ▼|AMGN369.85+3.41 (+0.93%) ▲|AMT165.29+3.18 (+1.96%) ▲|AMZN243.02-1.15 (-0.47%) ▼|AVGO367.72-6.18 (-1.65%) ▼|AXP350.63-5.40 (-1.52%) ▼|BA233.32-1.23 (-0.52%) ▼|BAC60.03+0.13 (+0.21%) ▲|BKNG181.93+0.90 (+0.50%) ▲|BLK1,006.34-4.87 (-0.48%) ▼|BMY58.46+1.76 (+3.10%) ▲|BNY152.00+2.04 (+1.36%) ▲|BRK-B506.60+0.02 (+0.00%) ▲|C141.79-2.07 (-1.44%) ▼|CAT914.32-55.60 (-5.73%) ▼|CL94.66+1.27 (+1.36%) ▲|CMCSA23.67+0.29 (+1.22%) ▲|COF202.80-3.70 (-1.79%) ▼|COP106.24+2.66 (+2.57%) ▲|COST948.98-1.27 (-0.13%) ▼|CRM171.50+5.85 (+3.53%) ▲|CSCO112.89-1.09 (-0.96%) ▼|CVS104.02+1.94 (+1.90%) ▲|CVX171.31+3.21 (+1.91%) ▲|DE598.40-36.85 (-5.80%) ▼|DHR193.78+0.16 (+0.08%) ▲|DIS97.82+0.41 (+0.42%) ▲|DUK128.98+3.01 (+2.39%) ▲|EMR137.78-3.78 (-2.67%) ▼|FDX313.25+3.32 (+1.07%) ▲|GD376.63-0.26 (-0.07%) ▼|GE366.92-11.76 (-3.11%) ▼|GEV1,038.56-113.48 (-9.85%) ▼|GILD134.36+4.75 (+3.66%) ▲|GM75.79-2.06 (-2.65%) ▼|GOOG365.50+0.60 (+0.16%) ▲|GOOGL368.52+2.06 (+0.56%) ▲|GS1,043.92-11.37 (-1.08%) ▼|HD346.12-4.53 (-1.29%) ▼|HON223.90-7.28 (-3.15%) ▼|IBM310.71+11.19 (+3.74%) ▲|INTC109.92-12.28 (-10.05%) ▼|INTU283.35+11.21 (+4.12%) ▲|ISRG426.55-6.28 (-1.45%) ▼|JNJ268.93+9.60 (+3.70%) ▲|JPM337.90+0.18 (+0.05%) ▲|KO84.24+1.28 (+1.54%) ▲|LIN536.26-4.27 (-0.79%) ▼|LLY1,229.10+29.04 (+2.42%) ▲|LMT537.36-0.65 (-0.12%) ▼|LOW221.98-1.81 (-0.81%) ▼|LRCX325.67-24.54 (-7.01%) ▼|MA532.77-0.33 (-0.06%) ▼|MCD282.47+2.97 (+1.06%) ▲|MDLZ60.27+1.10 (+1.86%) ▲|MDT84.49+1.43 (+1.72%) ▲|META604.81+4.52 (+0.75%) ▲|MMM157.00-2.15 (-1.35%) ▼|MO73.06+1.18 (+1.64%) ▲|MRK129.34+2.56 (+2.02%) ▲|MS220.97-1.13 (-0.51%) ▼|MSFT393.84+7.10 (+1.84%) ▲|MU922.13-62.63 (-6.36%) ▼|NEE88.25+0.81 (+0.93%) ▲|NFLX76.86+0.84 (+1.11%) ▲|NKE43.13-0.22 (-0.50%) ▼|NOW112.81+4.88 (+4.52%) ▲|NVDA195.21-0.34 (-0.17%) ▼|ORCL140.40-3.36 (-2.34%) ▼|PEP146.09+2.80 (+1.95%) ▲|PFE24.13+0.41 (+1.71%) ▲|PG151.56+2.25 (+1.51%) ▲|PLTR135.83+3.29 (+2.48%) ▲|PM186.98+2.22 (+1.20%) ▲|QCOM182.41-4.07 (-2.18%) ▼|RTX201.80+0.43 (+0.21%) ▲|SBUX103.24+1.13 (+1.11%) ▲|SCHW101.24+0.62 (+0.62%) ▲|SO98.06+2.07 (+2.16%) ▲|SPG229.23+4.23 (+1.88%) ▲|T20.98+0.40 (+1.92%) ▲|TMO516.78-0.82 (-0.16%) ▼|TMUS187.81+6.02 (+3.31%) ▲|TSLA407.68-12.09 (-2.88%) ▼|TXN292.00-11.50 (-3.79%) ▼|UBER73.41+0.99 (+1.36%) ▲|UNH426.99+9.00 (+2.15%) ▲|UNP283.00+0.41 (+0.14%) ▲|UPS112.12+2.10 (+1.91%) ▲|USB63.14+0.31 (+0.49%) ▲|V350.36-6.89 (-1.93%) ▼|VZ42.74+0.67 (+1.58%) ▲|WFC87.23-0.22 (-0.25%) ▼|WMT111.71+1.06 (+0.96%) ▲|XOM140.14+3.70 (+2.71%) ▲|AAPL314.37+1.71 (+0.55%) ▲|ABBV258.40+3.64 (+1.43%) ▲|ABT96.54+0.91 (+0.95%) ▲|ACN143.40+6.44 (+4.70%) ▲|ADBE230.12+12.05 (+5.52%) ▲|AMAT542.03-50.76 (-8.56%) ▼|AMD514.69-37.36 (-6.77%) ▼|AMGN369.85+3.41 (+0.93%) ▲|AMT165.29+3.18 (+1.96%) ▲|AMZN243.02-1.15 (-0.47%) ▼|AVGO367.72-6.18 (-1.65%) ▼|AXP350.63-5.40 (-1.52%) ▼|BA233.32-1.23 (-0.52%) ▼|BAC60.03+0.13 (+0.21%) ▲|BKNG181.93+0.90 (+0.50%) ▲|BLK1,006.34-4.87 (-0.48%) ▼|BMY58.46+1.76 (+3.10%) ▲|BNY152.00+2.04 (+1.36%) ▲|BRK-B506.60+0.02 (+0.00%) ▲|C141.79-2.07 (-1.44%) ▼|CAT914.32-55.60 (-5.73%) ▼|CL94.66+1.27 (+1.36%) ▲|CMCSA23.67+0.29 (+1.22%) ▲|COF202.80-3.70 (-1.79%) ▼|COP106.24+2.66 (+2.57%) ▲|COST948.98-1.27 (-0.13%) ▼|CRM171.50+5.85 (+3.53%) ▲|CSCO112.89-1.09 (-0.96%) ▼|CVS104.02+1.94 (+1.90%) ▲|CVX171.31+3.21 (+1.91%) ▲|DE598.40-36.85 (-5.80%) ▼|DHR193.78+0.16 (+0.08%) ▲|DIS97.82+0.41 (+0.42%) ▲|DUK128.98+3.01 (+2.39%) ▲|EMR137.78-3.78 (-2.67%) ▼|FDX313.25+3.32 (+1.07%) ▲|GD376.63-0.26 (-0.07%) ▼|GE366.92-11.76 (-3.11%) ▼|GEV1,038.56-113.48 (-9.85%) ▼|GILD134.36+4.75 (+3.66%) ▲|GM75.79-2.06 (-2.65%) ▼|GOOG365.50+0.60 (+0.16%) ▲|GOOGL368.52+2.06 (+0.56%) ▲|GS1,043.92-11.37 (-1.08%) ▼|HD346.12-4.53 (-1.29%) ▼|HON223.90-7.28 (-3.15%) ▼|IBM310.71+11.19 (+3.74%) ▲|INTC109.92-12.28 (-10.05%) ▼|INTU283.35+11.21 (+4.12%) ▲|ISRG426.55-6.28 (-1.45%) ▼|JNJ268.93+9.60 (+3.70%) ▲|JPM337.90+0.18 (+0.05%) ▲|KO84.24+1.28 (+1.54%) ▲|LIN536.26-4.27 (-0.79%) ▼|LLY1,229.10+29.04 (+2.42%) ▲|LMT537.36-0.65 (-0.12%) ▼|LOW221.98-1.81 (-0.81%) ▼|LRCX325.67-24.54 (-7.01%) ▼|MA532.77-0.33 (-0.06%) ▼|MCD282.47+2.97 (+1.06%) ▲|MDLZ60.27+1.10 (+1.86%) ▲|MDT84.49+1.43 (+1.72%) ▲|META604.81+4.52 (+0.75%) ▲|MMM157.00-2.15 (-1.35%) ▼|MO73.06+1.18 (+1.64%) ▲|MRK129.34+2.56 (+2.02%) ▲|MS220.97-1.13 (-0.51%) ▼|MSFT393.84+7.10 (+1.84%) ▲|MU922.13-62.63 (-6.36%) ▼|NEE88.25+0.81 (+0.93%) ▲|NFLX76.86+0.84 (+1.11%) ▲|NKE43.13-0.22 (-0.50%) ▼|NOW112.81+4.88 (+4.52%) ▲|NVDA195.21-0.34 (-0.17%) ▼|ORCL140.40-3.36 (-2.34%) ▼|PEP146.09+2.80 (+1.95%) ▲|PFE24.13+0.41 (+1.71%) ▲|PG151.56+2.25 (+1.51%) ▲|PLTR135.83+3.29 (+2.48%) ▲|PM186.98+2.22 (+1.20%) ▲|QCOM182.41-4.07 (-2.18%) ▼|RTX201.80+0.43 (+0.21%) ▲|SBUX103.24+1.13 (+1.11%) ▲|SCHW101.24+0.62 (+0.62%) ▲|SO98.06+2.07 (+2.16%) ▲|SPG229.23+4.23 (+1.88%) ▲|T20.98+0.40 (+1.92%) ▲|TMO516.78-0.82 (-0.16%) ▼|TMUS187.81+6.02 (+3.31%) ▲|TSLA407.68-12.09 (-2.88%) ▼|TXN292.00-11.50 (-3.79%) ▼|UBER73.41+0.99 (+1.36%) ▲|UNH426.99+9.00 (+2.15%) ▲|UNP283.00+0.41 (+0.14%) ▲|UPS112.12+2.10 (+1.91%) ▲|USB63.14+0.31 (+0.49%) ▲|V350.36-6.89 (-1.93%) ▼|VZ42.74+0.67 (+1.58%) ▲|WFC87.23-0.22 (-0.25%) ▼|WMT111.71+1.06 (+0.96%) ▲|XOM140.14+3.70 (+2.71%) ▲|
18.4 C
New York
Tuesday, July 7, 2026

Tag: release

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

PageUp Infuses AI Across its Hiring Platform to Automate Repetitive Tasks and Accelerate Smart Hiring

PageUp's Mid-Year Release Helps Overwhelmed Recruiting Teams Navigate Overwhelming Applicant Volumes to Hire More Efficiently

RDDT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Reddit, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reddit, Inc. (“Reddit” or “the Company”) (NYSE: RDDT) and certain of its officers.

vivenu dévoile Customer Segments : votre boussole numérique pour maximiser la valeur de votre audience

DÜSSELDORF, Allemagne, 17 août 2025 (GLOBE NEWSWIRE) -- vivenu, la principale plateforme de billetterie professionnelle du spectacle vivant, annonce le lancement de vivenu Customer Segments, une fonctionnalité conçue pour révolutionner la manière dont les organisateurs d’événements interagissent avec leur audience, l’appréhendent et la monétisent. Cette avancée stratégique permet à vivenu de se positionner comme une plateforme d’expérience événementielle (EXP) holistique, dépassant ainsi le cadre de la billetterie traditionnelle.

KLC INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against KinderCare Learning Companies, Inc. and Announces Opportunity for Investors with...

SAN DIEGO, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare’s October 2024 initial public offering (“IPO”), have until October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424 (D. Or.), the KinderCare class action lawsuit charges KinderCare as well as certain of KinderCare’s top executives and directors, KinderCare’s controlling shareholder, and the underwriters of the IPO with violations of the Securities Act of 1933.

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages CTO Realty Growth, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action –...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of CTO Realty Growth, Inc. (NYSE: CTO, CTO-PA) between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 7, 2025.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline –...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI). Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Groupon, Inc. – GRPN

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Designer Brands Inc. – DBI

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Designer Brands Inc.  (“Designer Brands” or the “Company”) (NYSE: DBI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. – PETS

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets

Stealth Aerospace, the aftermarket division of FDH Electronics, has been named an approved distribution channel by Leach International Corporation.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. – NEO

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Bad Credit Check Loan Guaranteed Approval: RadCred Launches AI Automation For No Credit Check Loan Instant Approval For US Borrowers In USA

Glendale, CA, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Radcred, a trusted U.S. consumer lending brand, RadCred understands that access to emergency funds remains one of the biggest challenges for Americans with poor or limited credit. Federal Reserve data shows that more than 60% of adults cannot cover a $400 unexpected expense without borrowing or selling assets. Traditional banks often reject applicants with low scores, leaving millions to search online for alternatives such as bad credit check loans with guaranteed approval or instant approval no credit check loans.

Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers – BHVN

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRelease